bi-907828
boehringer ingelheim
['bi 907828', 'solid tumor']
the mdm2 p53 antagonist bi 907828 in patients with advanced or metastatic solid tumors: results of a phase ia, first-in-human, dose-escalation study | cancer discovery | american association for cancer research | #asco23 
Associate Scientific Director, Computational Biology Oncology at @boehringer 🧬 Data Scientist & KRAS, MDM2 , HER2 Research. Tweets are my own.